KAMICINE 500
-
Chemical Name:
Amikacin (Sulfate) -
Therapeutic Category:
Antimicrobial -
Pharmacologic Category:
Antibiotic, Aminoglycoside -
Pharmaceutical Form:
Ampoule -
Composition:
Amikacin (Sulfate) 500mg
KAMICINE
Injection (Ampoule)
Amikacin (Sulfate)
1.PHARMACOLOGY:
KAMICINE is a semisynthetic aminogolycoside antibiotic. It is active against many gram-negative bacteria and some strains of staphylococci. Amikacin is bactericidal and acts by inhibiting protein synthesis in the bacterial cell.
It is used in the treatment of severe infection caused by susceptible bacteria which are resistant to gentamycin and tobramycin and may be used in combination with betalactam (penicillin and cephalosporins).
2.INDICATIONS:
KAMICINE is used in the treatment of:
- Septicaemia.
- Respiratory tract infections.
- Bones and joints infections.
- Skin and soft tissue infections.
- Intra-abdominal infections.
- Urinary tract infections.
- Meningitis.
KAMICINE is used for the prophylaxis of post-operative infections.
3.CONTRA-INDICATIONS:
- Hypersensitivity to Amikacin or to other aminoglycosides.
- Pregnancy.
- Myasthenia gravis.
4.SIDE EFFECTS:
KAMICINE may cause irreversible ototoxicity (hearing loss, vertigo) and reversible nephrotoxicity (acute renal failure). Other side effects include: nausea, blood dyscrasias, respiratory depression, hypersensitivity reactions and pain at the injection site.
5.PRECAUTIONS:
- Patients treated with Amikacin should be under close clinical observation.
- KAMICINE should be administered separately and should not be mixed with other agents in syringes.
- KAMICINE should be discontinued immediately if a symptoms of ototoxicity appears.
- KAMICINE should be given with caution to elderly patients, infants, patients with neuromuscular disturbances or patients with renal failure who require reduced doses.
6.DRUG INTERACTIONS:
- Concurrent use of cephalosporins may increase the risk of nephrotoxicity.
- Concurrent use of frusemide may increase the risk of ototoxicity.
- KAMICINE should not be given to patients taking neuromuscular blocking agents.
7.DOSAGE AND ADMINISTRATION:
- KAMICINE may be given intramuscularly and intravenously or intravenous infusion.
- Course of treatment should be limited to 7-10 days.
- The total dose for adults should not exceed 15g.
- Adults and Children: 15mg/kg bodyweight daily in divided doses every 8 or 12 hours by intramuscular injection up to a maximum of 1.5g daily in adults.
The same doses may be given slow by intravenous injection over 2 to 3 minutes or by intravenous infusion.
In adults, 500 mg in 100 to 200 ml of diluent has been infused over 30 to 60 minutes and less fluid should be given to children and infused in 1-2 hours.
8.PACKAGING & COMPOSITION:
- KAMICINE 100 – Injection: A Pack of 3, 5 or 25 ampoules of 2mL. Each ampoule (2 mL) contains Amikacin (Sulfate) 100 mg.
- KAMICINE 500 – Injection: A Pack of 3, 5 or 25 ampoules of 2mL. Each ampoule (2 mL) contains Amikacin (Sulfate) 500 mg.
9.STORAGE CONDITIONS:
Store KAMICINE – Injection at temperature between (15-30)°C.
Related Products
